I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV709179552US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

1430.

Dated: April 16 2007

Signature: V(VVV)
(Valerie Cohen)

Patent Docket No. 223002099101

APR 1 6 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Vincenzo SCARLATO et al.

Serial No.: 10/695,499

Filing Date: October 28, 2003

For: MENINGOCOCCAL ANTIGENS

Examiner: J. Graser

Group Art Unit: 1645

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literatures are submitted herewith. The Examiner is requested to make these documents of record.

04/18/2007 HLE333 00000051 031952 10695499

02 FC:1806

180.00 DA

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
	Within three months of the application filing date or before mailing of a first Office Action
	on the merits; accordingly, no fee or separate requirements are required. However, if
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
$\boxtimes$	After receipt of a first Office Action on the merits but before mailing of a final Office
	Action or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
	to this submission in duplicate.
	A Certification under 2 is provided above; accordingly; no fee is believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)
	Applicants would appreciate the Examiner initialing and returning the Form

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 223002099101.

Dated: April 16, 2007

Respectfully submitted,

Otis Littlefield

Registration No.: 48,751

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

(415) 268-6846

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1
--------------

Complete if Known				
Application Number	10/695,499			
Filing Date	October 28, 2003			
First Named Inventor	Vincenzo SCARLATO			
Art Unit	1645			
Examiner Name	J. Graser			
Attorney Docket Number	223002099101			

·	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
•	1.	US-6,709,660	03-23-2004	Scarlato et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (boo magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		, <b>T</b> <sup>2</sup>			
	2.	PARALKAR, et al. (1994). "Cloning the Human Gene for Macrophage Migration Inhibitory Factor (MIF)," Genomics, 19:48-51.				
	3.	BERNHAGEN, et al. (1994) "Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF)," Biochemistry, 33:14144-14155.				
	4.	WATARAI, et al. (2000). "Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF," PNAS Early Edition, p. 1-6.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered
of 2200950	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.